Rapid communication · 29 May 2025
Research articlePublished 10 Oct 2019
Effect of Adding Vildagliptin to Metformin on Antioxidant State, Inflammatory, and Atherothrombotic Markers in Newly Diagnosed Patients with Type 2 Diabetes Mellitus
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Objective: This study aimed to evaluate the effect of adding vildagliptin to metformin therapy on major CV risk parameters in newly diagnosed patients with type 2 diabetes mellitus (T2DM). Methods: Forty three eligible patients were prospectively randomized to receive combined vildagliptin/ metformin therapy or metformin alone. Anthropometric measurements, blood pressure (BP), glycated hemoglobin (HbA1c), lipid profile, plasminogen activator inhibitor-1 (PAI-1), high sensitivity C-reactive protein (hs- CRP), and total antioxidant capacity (TAC) were assessed at baseline and after 12 weeks. Results: Forty patients completed the study (20 in each group). At baseline, no significant differences were observed between groups in all studied parameters. After 12 weeks, combined vildagliptin/metformin showed significant reductions in HbA1c (Δ change: -2.68 ± 2.24 versus -1.37 ± 1.8%, P=0.043, respectively), systolic BP (Δ change: -12.5 ± 13.03 versus -3.75 ± 11.57 mmHg, p=0.012, respectively), diastolic BP (Δ change: -10.25 ± 9.39 versus -2.5 ± 9.39 mmHg, p=0.009, respectively), triglycerides (Δ change: -9.7 ± 18.48 versus 10.35 ± 27.36 mg/dl, p=0.037, respectively), and PAI-1(Δ change: -7.93 ± 17.11 versus 3.9 ± 19.39 ng/ml, p=0.048, respectively) as compared to metformin monotherapy. No significant differences were observed between both groups regarding their effects on other studied parameters. Conclusion: Adding vildagliptin to metformin resulted in a decrease in PAI-1, systolic and diastolic BP, triglycerides, and HbA1c with no significant changes in hs-CRP, TAC, and other lipid markers.
Subjects
Diabetes & EndocrinologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Diabetes & Metabolism.
Rapid communication · 29 May 2025
Genetic and epigenetic markers for gdm risk
Short communication · 29 May 2025
Metabolic syndrome: Diet, timed eating, supplements
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Diabetes & Metabolism
- SubjectDiabetes & Endocrinology
- BylineArticles whose byline prints “Bassant M Mahboub”
- BylineArticles whose byline prints “Sahar M El-Haggar”
- BylineArticles whose byline prints “Yasser M Abdelraouf”
- BylineArticles whose byline prints “Gamal A Elazab”